Exklusiver Live-Stream direkt von der World of Trading - 2 Tage mit einzigartigen Themen und Experten. Kostenlos teilnehmen + Videos erhalten. -w-
22.10.2018 14:51:46

DGAP-PVR: STADA Arzneimittel AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

DGAP Voting Rights Announcement: STADA Arzneimittel AG
STADA Arzneimittel AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

22.10.2018 / 14:51
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Notification of Major Holdings

1. Details of issuer
STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Germany

2. Reason for notification
  Acquisition/disposal of shares with voting rights
  Acquisition/disposal of instruments
  Change of breakdown of voting rights
X Other reason:
Lapse of financial instruments due to the tendering of shares into the delisting tender offer by certain shareholders pursuant to irrevocable undertaking

3. Details of person subject to the notification obligation
Name: City and country of registered office:
Cinven Capital Management (VI) General Partner Limited Saint Peter Port, Guernsey
Channel Islands

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
Nidda Healthcare GmbH

5. Date on which threshold was crossed or reached:
17 Oct 2018

6. Total positions
  % of voting rights attached to shares
(total of 7.a.)
% of voting rights through instruments
(total of 7.b.1 + 7.b.2)
total of both in %
(7.a. + 7.b.)
total number of voting rights of issuer
Resulting situation 65.31 % 0.0008 % 65.31 % 62,342,440
Previous notification 65.31 % 7.08 % 72.39 % /

7. Notified details of the resulting situation
a. Voting rights attached to shares (Sec.s 33, 34 WpHG)
ISIN absolute in %
  direct
(Sec. 33 WpHG)
indirect
(Sec. 34 WpHG)
direct
(Sec. 33 WpHG)
indirect
(Sec. 34 WpHG)
DE0007251803 40,716,644 % 65.31 %
Total 40,716,644 65.31 %

b.1. Instruments according to Sec. 38 para. 1 No. 1 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Voting rights absolute Voting rights in %
Tender under domination and profit and loss transfer agreement n/a n/a 491 0.0008 %
    Total 491 0.0008 %

b.2. Instruments according to Sec. 38 para. 1 No. 2 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Cash or physical settlement Voting rights absolute Voting rights in %
%
      Total %

8. Information in relation to the person subject to the notification obligation
  Person subject to the notification obligation is not controlled and does itself not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer (1.).
X Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name % of voting rights (if at least held 3% or more) % of voting rights through instruments (if at least held 5% or more) Total of both (if at least held 5% or more)
Cinven Capital Management (VI) General Partner Limited % % %
Cinven Capital Management (VI) Limited Partnership Incorporated % % %
Sixth Cinven Fund (No. 1) Limited Partnership % % %
Ciddan S.à r.l. % % %
Nidda Topco S.à r.l. % % %
Nidda Midco S.à r.l. % % %
Nidda German Topco GmbH % % %
Nidda German Midco GmbH % % %
Nidda BondCo GmbH % % %
Nidda Healthcare Holding GmbH % % %
Nidda Healthcare GmbH 65.31 % % 65.31 %
 
Cinven Capital Management (VI) General Partner Limited % % %
Cinven Capital Management (VI) Limited Partnership Incorporated % % %
Sixth Cinven Fund (No. 2) Limited Partnership % % %
Ciddan S.à r.l. % % %
Nidda Topco S.à r.l. % % %
Nidda Midco S.à r.l. % % %
Nidda German Topco GmbH % % %
Nidda German Midco GmbH % % %
Nidda BondCo GmbH % % %
Nidda Healthcare Holding GmbH % % %
Nidda Healthcare GmbH 65.31 % % 65.31 %
 
Cinven Capital Management (VI) General Partner Limited % % %
Cinven Capital Management (VI) Limited Partnership Incorporated % % %
Sixth Cinven Fund (No. 3) Limited Partnership % % %
Ciddan S.à r.l. % % %
Nidda Topco S.à r.l. % % %
Nidda Midco S.à r.l. % % %
Nidda German Topco GmbH % % %
Nidda German Midco GmbH % % %
Nidda BondCo GmbH % % %
Nidda Healthcare Holding GmbH % % %
Nidda Healthcare GmbH 65.31 % % 65.31 %
 
Cinven Capital Management (VI) General Partner Limited % % %
Cinven Capital Management (VI) Limited Partnership Incorporated % % %
Sixth Cinven Fund (No. 4) Limited Partnership % % %
Ciddan S.à r.l. % % %
Nidda Topco S.à r.l. % % %
Nidda Midco S.à r.l. % % %
Nidda German Topco GmbH % % %
Nidda German Midco GmbH % % %
Nidda BondCo GmbH % % %
Nidda Healthcare Holding GmbH % % %
Nidda Healthcare GmbH 65.31 % % 65.31 %

9. In case of proxy voting according to Sec. 34 para. 3 WpHG

Date of general meeting:
Holding position after general meeting: % (equals voting rights)

10. Other explanatory remarks:
 



22.10.2018 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Germany
Internet: www.stada.de

 
End of News DGAP News Service

735971  22.10.2018 

fncls.ssp?fn=show_t_gif&application_id=735971&application_name=news&site_id=smarthouse

Analysen zu STADAmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!